Bernstein upgraded 3M Company from Underperform to Market Perform on September 26 and raised its price target from $145 to $171, sending the shares up 1.4%. Analyst Varun Govindaraj cited a refreshed view of 3M's transformation after a recent meeting with management, pointing to an R&D "factory" model, a short-cycle recovery fueled by AI capital spending, and lower PFAS legal risk, and he lifted his organic growth forecast to 3.5% to 4% from roughly 3%. Bernstein stopped short of a buy rating, however, suggesting the stock looks roughly fully valued after its recent run, with even the new $171 target implying limited upside. The legal overhang is paused rather than resolved: 3M still faces more than 15,000 personal injury cases, the October 2025 kidney-cancer bellwether trial has been vacated with no replacement date set as of August, and no verdict or settlement has established a valuation anchor. Much of the operational turnaround already appears priced in, with second-quarter adjusted organic growth of 5.4%, a forward price-to-sales ratio of 3.33x that sits about 27% above its 5-year average of 2.62x, and $13.16 billion in debt against $5.30 billion in cash before any future PFAS settlements.
3M CompanyBernstein upgraded 3M to Market Perform and raised its price target to $171, citing improved transformation outlook and lower PFAS legal risk.
Vicor Corporation